Alkem Laboratories block deal: 1.5% stake sold 2026

Why Alkem Laboratories shares are in focus

Shares of Alkem Laboratories Ltd are set to draw attention heading into Wednesday’s trade after a large promoter-side stake sale through block deals on the NSE. Exchange data showed nearly 17.88 lakh shares changed hands at an average price of Rs 5,200 apiece. The transaction size worked out to about Rs 929.87 crore, commonly rounded to around Rs 930 crore in reports.

The selling was concentrated in two promoter-linked entities, while the buying was spread across a mix of domestic mutual funds and global institutional investors. The deal is also being tracked because it resulted in a clean exit by one promoter-group member and reduced overall promoter ownership in the company.

Deal snapshot: size, price and structure

Block deal data indicated that 17,88,220 shares representing a 1.49 percent stake were offloaded in Alkem Laboratories. The price was Rs 5,200 per share. Separate reports described the sale as about 1.5 percent of equity and pegged the total value at around Rs 930 crore.

The selling price was also reported to be at a discount of about 2.2 percent to Alkem’s previous closing price of Rs 5,318. By the end of the trading session after the block activity, Alkem Laboratories shares fell 1.42 percent to close at Rs 5,239 on the NSE.

Sellers: Jayanti Sinha exits, family trust also offloads

Two promoter entities were identified as sellers. Jayanti Sinha, part of the promoter group, sold her entire shareholding in the company. She offloaded 12,38,220 shares, equal to a 1.04 percent stake, at Rs 5,200 per share for Rs 643.87 crore.

The Samprada & Nanhamati Singh Family Trust was the second seller. It sold 5,50,000 shares for Rs 286 crore. Together, these two entities accounted for the full 17.88 lakh shares sold in the block deal.

In another detail cited in reports, the trust was represented by authorised individual beneficiaries and sellers Sandeep Singh and Jayanti Sinha, as per a term sheet referenced by CNBC-TV18.

Buyers: nine institutions, mutual funds lead allocations

On the buying side, nine domestic and global investors were reported to have picked up the shares. The list included ICICI Prudential Mutual Fund, HDFC Mutual Fund, Edelweiss Mutual Fund, Nippon India Mutual Fund, DSP Mutual Fund, BNP Paribas Arbitrage, Societe Generale, Morgan Stanley Asia Singapore, and Goldman Sachs Bank Europe.

ICICI Prudential Mutual Fund and HDFC Mutual Fund were the largest buyers. ICICI Prudential Mutual Fund acquired about 9.03 to 9.04 lakh shares for Rs 469.83 crore, while HDFC Mutual Fund bought about 5.09 to 5.10 lakh shares for around Rs 265 crore.

DSP Mutual Fund purchased 86,538 shares for Rs 45 crore. Reports also said BNP Paribas Arbitrage, Societe Generale, Nippon India Mutual Fund, Morgan Stanley Asia Singapore, Goldman Sachs Bank Europe, and Edelweiss Mutual Fund each purchased 48,090 shares for Rs 25 crore. Another data point mentioned that Goldman Sachs Bank Europe, Edelweiss MF, Morgan Stanley Asia Singapore PTE, Nippon India MF and BNP Paribas Arbitrage bought 48,090 shares each.

Pricing details: floor price and reported lock-up

The block deal followed reports that the Samprada and Nanhamati Family Trust was looking to sell up to a 1.5 percent stake. A term sheet accessed by CNBC-TV18 indicated a floor price of Rs 5,200 per share.

The same term sheet also specified a 90-day lock-up period on any further sale of shares by the sellers. The executed deal price matched the floor price cited in that report.

Promoter holding changes after the transaction

Following the stake sale, Jayanti Sinha exited Alkem Laboratories, according to reports. The transaction also reduced total promoter shareholding in the company. Promoter holding dropped to 49.71 percent from 51.20 percent after the block deal, as cited in the coverage.

For investors, the immediate relevance is not only the size of the deal, but also the shift in promoter ownership levels and the entry of multiple institutions on the other side of the trade.

Market reaction: stock closes lower after block activity

Alkem Laboratories shares closed 1.42 percent lower at Rs 5,239 on the NSE after the block deal. The deal price of Rs 5,200 was also reported as a 2.2 percent discount to the previous close of Rs 5,318.

Such discounts are common in block transactions due to the size of shares being placed in one shot. In this case, the breadth of buyers included both domestic mutual funds and overseas institutions, based on deal breakdowns cited in reports.

Separate development: semaglutide launch in India

In a separate update reported the same day, Alkem Laboratories said it launched semaglutide in single-shot pre-filled syringes in India. The product was introduced at a starting price of Rs 350. The company was described as the first in the country to offer this format, based on the report.

This corporate development arrived alongside the block deal news and may also contribute to investor focus, as it signals product activity even as promoter-linked entities reduced their holding.

Key numbers from the Alkem Laboratories block deal

What investors will watch next

The immediate takeaway from the transaction is that promoter-linked entities executed a clean, fully allocated sale of about 1.5 percent equity at Rs 5,200 per share, with nine institutional investors taking the other side. The deal also resulted in Jayanti Sinha exiting the company and reduced total promoter ownership below 50 percent, as per the reported post-deal shareholding.

Beyond the block trade, investors may track whether the company provides further updates around the newly launched semaglutide pre-filled syringes, and whether there are any additional disclosures tied to the term sheet elements referenced in reports, including the stated lock-up period.